Inflammation and Risk Prediction in Patients With Abdominal Aortic Aneurysm
Recruitment status was Recruiting
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Inflammation and Risk Prediction in Patients With Abdominal Aortic Aneurysm|
- Give more details that may enable us to better assess the chance of AAA expansion or rupture [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||July 2008|
|Estimated Study Completion Date:||July 2013|
|Estimated Primary Completion Date:||July 2013 (Final data collection date for primary outcome measure)|
Cumulative experimental and pathological evidence support the postulate that inflammation may serve as the unifying concept in the pathogenesis of atherosclerosis and its complications. Aneurysmal disease is associated with inflammatory cell infiltrate and enzymatic degradation of the vessel wall. Although the risk of abdominal aortic aneurysm (AAA) rupture relates to the maximum cross-sectional diameter, rapid expansion of the aortic diameters preceding fissuration and rupture has been observed in AAA independently of their initial size. However, current diagnostic modalities stratify risk of AAA rupture based solely on the size of the aneurysm without factoring potentially useful information derivable from the degree of aneurysmal wall inflammatory response.
We propose to utilize fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging co-registered with structural computerized tomography (CT) images for the in vivo localization and quantification of vascular inflammation in patients with AAA in order to determine whether increased inflammation within the walls of the aneurysm correlates with rapid enlargement of AAA (change in aneurysmal diameter within 6 months), symptoms, thrombosis, or intervention for ruptured, leaking, rapidly expanding, or painful AAAs.
In patients with underlying abdominal aortic aneurysm (AAA), the progression of disease i.e. expansion is associated with increased inflammation within the aneurysm wall as characterized by FDG-PET/CT, and the degree of inflammation is a risk predictor for adverse events.
Prior studies have demonstrated that FDG uptake is greater in inflamed tissues, such as infectious foci and tumors. In chronic inflammatory lesions and malignancies, FDG uptake is increased in macrophage-dense regions. The relatively high uptake of FDG by macrophages is attributed to the relatively high metabolic rates of macrophages, and the inability of macrophages to store glycogen, making them more reliant upon external glucose as a source of fuel. Activation of macrophages can further increase their glucose consumption. Both in animal models and humans, inflamed blood vessels have been shown to have an increased uptake of FDG. Several investigators have shown that FDG-PET can reliably detect inflammation in atherosclerosis. Thus detection of enhanced FDG uptake in the aneurysmal walls of patients with AAA may have potential significance.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00513773
|Contact: Terri Herrud, BS, CCRP||615 343 email@example.com|
|United States, Tennessee|
|Vanderbilt University Medical Center||Recruiting|
|Nashville, Tennessee, United States, 37232-8802|
|Contact: Terri Herrud, BS, CCRP 615-343-6426 firstname.lastname@example.org|
|Sub-Investigator: Marvin Kronenberg, MD|
|Sub-Investigator: William H Martin, MD|
|Sub-Investigator: Raul J Guzman, MD|
|Sub-Investigator: Douglas E Vaughan, MD|
|Sub-Investigator: Thomas C Naslund, MD|
|Sub-Investigator: MacRae Linton, MD|
|Sub-Investigator: Sergio Fazio, MD, PHD|
|Sub-Investigator: Ronald Walker, MD|
|Sub-Investigator: Dominique Delbeke, MD|
|Sub-Investigator: John Patton, MD|
|Principal Investigator:||Uchechukwu Sampson, MD||Vanderbilt University|